Circulating Nucleic Acids in the Assessment of Endogenous Growth Hormone Production

There is growing concern about the use of recombinant human growth hormone (rhGH) by individuals taking part in competitive sports. Although rhGH is banned by the international organizations, the detection of GH doping is difficult. We postulated that rhGH will suppress endogenous GH production, which can be assessed by the measurement of mRNA for GH and growth hormone–releasing hormone (GHRH). In order to prove this concept, we undertook a pilot study to examine whether circulating nucleic acids are useful in the detection of endogenous GH production. Blood samples were collected into PAXgene tubes from 37 healthy controls and 12 acromegalic patients. RNA was extracted from the samples, cDNA was obtained, and the quantities of mRNA for GH and GHRH were measured using real‐time PCR. In acromegalic patients, median mRNA concentration for GHRH (corrected for β‐actin mRNA) was 30.7 times lower than in controls (median delta CT) value of −0.128 versus 3.927, P < 0.001). There was a significant correlation between serum IGF‐1 SD score and mRNA for GHRH (r= 0.407). In acromegalic patients, mRNA for GH was significantly higher than in controls (median values of −4.694 versus −0.044, P < 0.05). As GH production is known to decline with age, we also examined mRNA for GH and GHRH according to age subgroups. Both markers were significantly lower in the older age group (>50 years) compared to the younger age group (<34 years). These results show that mRNA for GH and GHRH can be detected in the peripheral circulation and raises the possibility of using these markers in the detection of exogenously administered GH.

[1]  J. C. Tsang,et al.  Circulating nucleic acids in plasma/serum , 2007, Pathology.

[2]  P. Sönksen,et al.  Challenges in detecting the abuse of growth hormone in sport. , 2005, Clinical chemistry.

[3]  A. Sartorio,et al.  Growth hormone abuse: methods of detection , 2005, Trends in Endocrinology & Metabolism.

[4]  Y. Lo,et al.  Circulating corticotropin-releasing hormone mRNA in maternal plasma: relationship with gestational age and severity of preeclampsia. , 2004, Clinical chemistry.

[5]  Gretchen Vogel,et al.  A Race to the Starting Line , 2004, Science.

[6]  A. Klibanski,et al.  Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. , 2003, The Journal of clinical endocrinology and metabolism.

[7]  G. Arnaldi,et al.  Reduced expression of the growth hormone and type 1 insulin‐like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor , 2003, Clinical endocrinology.

[8]  J. Veldhuis,et al.  Three-peptide control of pulsatile and entropic feedback-sensitive modes of growth hormone secretion: modulation by estrogen and aromatizable androgen. , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[9]  R. Chiu,et al.  mRNA of placental origin is readily detectable in maternal plasma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[11]  M. Bidlingmaier,et al.  Doping with Growth Hormone , 2001, Journal of pediatric endocrinology & metabolism : JPEM.

[12]  T. Solomon,et al.  Emerging viral diseases , 2001 .

[13]  M. Bidlingmaier,et al.  Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  S. Shalet,et al.  6 Ageing and growth hormone status , 1998 .

[15]  L. Frohman,et al.  Differential effects of central and peripheral administration of growth hormone (GH) and insulin-like growth factor on hypothalamic GH-releasing hormone and somatostatin gene expression in GH-deficient dwarf rats. , 1993, Endocrinology.

[16]  M. Blackman,et al.  Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. , 1992, The Journal of clinical endocrinology and metabolism.

[17]  A. Klibanski,et al.  Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  P. Sőnksen,et al.  Insulin, growth hormone and sport. , 2001, The Journal of endocrinology.

[19]  S. Shalet,et al.  Ageing and growth hormone status. , 1998, Bailliere's clinical endocrinology and metabolism.

[20]  M. Blackman,et al.  Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men. , 1993, The Journal of clinical endocrinology and metabolism.

[21]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .